Anti-TNF Response Prediction Using Biomarker Classifiers in RA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-TNF therapies exhibit inconsistent response rates, leading to delayed treatment and increased risks of side effects due to the inability to accurately predict which patients will benefit from the therapy, resulting in prolonged symptom progression and potential harm.
Innovation Solution
A method utilizing a classifier that assesses gene expression levels, single nucleotide polymorphisms (SNPs), and clinical characteristics to distinguish between responsive and non-responsive patients, enabling personalized treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-TNF therapy is administered to all RA patients, then some patients achieve disease remission, but response rates are inconsistent and many patients do not benefit while experiencing side effects
Solution Approach 1:
The patent applies preliminary action by developing and applying a machine learning classifier before anti-TNF therapy administration to predict patient response. The classifier analyzes multiple biomarkers and clinical characteristics to identify likely responders in advance, enabling selective treatment only for patients predicted to benefit, thereby avoiding side effects in non-responders while maintaining high response rates among treated patients
2Adaptability or versatility
If patients are switched to alternative therapies after failing anti-TNF treatment, then treatment options are explored, but the process takes over a year and disease progresses during this delay
Solution Approach 1:
The patent implements preliminary action by performing response prediction using the machine learning classifier before initiating anti-TNF therapy. This upfront assessment identifies likely non-responders who can be directed to alternative therapies immediately, avoiding the traditional sequential approach where patients cycle through multiple anti-TNF agents over a year before switching. The classifier enables immediate treatment optimization, preventing disease progression during the selection period
3Measurement precision
If machine learning classifiers are continuously updated with new data, then prediction accuracy improves, but implementation in clinical labs is difficult due to validation requirements
Solution Approach 1:
The patent applies dynamics by creating a flexible machine learning classifier system that can be retrained and updated with new data while maintaining clinical utility. The system architecture allows for periodic retraining with accumulating clinical data to improve prediction accuracy over time, while the validation framework enables controlled updates without requiring complete system re-validation, thus balancing adaptability with regulatory compliance
Data Source
AI summary
Presented herein are systems and methods for developing classifiers useful for predicting response to particular treatments. For example, in some embodiments, the present disclosure provides a method of treating subjects suffering from an autoimmune disorder, the method comprising administering an alternative to anti-TNF therapy to subjects who have been determined to be non-responsive via a classifier established to distinguish between responsive and non-responsive prior subjects in a cohort who have received the anti-TNF therapy.